SK282491B6 - Pyridazíndióny, spôsob a medziprodukty na ich výrobu, farmaceutický prostriedok s ich obsahom a ich použitie - Google Patents

Pyridazíndióny, spôsob a medziprodukty na ich výrobu, farmaceutický prostriedok s ich obsahom a ich použitie Download PDF

Info

Publication number
SK282491B6
SK282491B6 SK504-96A SK50496A SK282491B6 SK 282491 B6 SK282491 B6 SK 282491B6 SK 50496 A SK50496 A SK 50496A SK 282491 B6 SK282491 B6 SK 282491B6
Authority
SK
Slovakia
Prior art keywords
chloro
quinoline
hydroxy
dione
tetrahydropyridazino
Prior art date
Application number
SK504-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK50496A3 (en
Inventor
Thomas Michael Bare
Richard Bruce Sparks
James Roy Empfield
Timothy Wayne Davenport
Jeffrey Alan Mckinney
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939321854A external-priority patent/GB9321854D0/en
Priority claimed from GB9417171A external-priority patent/GB9417171D0/en
Application filed by Zeneca Limited filed Critical Zeneca Limited
Publication of SK50496A3 publication Critical patent/SK50496A3/sk
Publication of SK282491B6 publication Critical patent/SK282491B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
SK504-96A 1993-10-22 1994-10-20 Pyridazíndióny, spôsob a medziprodukty na ich výrobu, farmaceutický prostriedok s ich obsahom a ich použitie SK282491B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939321854A GB9321854D0 (en) 1993-10-22 1993-10-22 Pyridazino quinoline compounds
GB9417171A GB9417171D0 (en) 1994-08-25 1994-08-25 Pyridazino quinoline compounds
PCT/GB1994/002295 WO1995011244A1 (fr) 1993-10-22 1994-10-20 Composes de pyridazino quinoleine

Publications (2)

Publication Number Publication Date
SK50496A3 SK50496A3 (en) 1997-03-05
SK282491B6 true SK282491B6 (sk) 2002-02-05

Family

ID=26303731

Family Applications (1)

Application Number Title Priority Date Filing Date
SK504-96A SK282491B6 (sk) 1993-10-22 1994-10-20 Pyridazíndióny, spôsob a medziprodukty na ich výrobu, farmaceutický prostriedok s ich obsahom a ich použitie

Country Status (30)

Country Link
US (3) US5744471A (fr)
EP (2) EP1004582B1 (fr)
JP (1) JP3583132B2 (fr)
KR (1) KR100261209B1 (fr)
CN (1) CN1053189C (fr)
AT (2) ATE198072T1 (fr)
AU (2) AU688393B2 (fr)
CA (1) CA2171332A1 (fr)
CZ (1) CZ292311B6 (fr)
DE (2) DE69434380T2 (fr)
DK (2) DK1004582T3 (fr)
ES (2) ES2154686T3 (fr)
FI (2) FI113865B (fr)
GB (1) GB9420590D0 (fr)
GR (1) GR3035080T3 (fr)
HK (1) HK1013997A1 (fr)
HU (1) HUT74161A (fr)
IL (1) IL111266A (fr)
MY (2) MY124316A (fr)
NO (1) NO306995B1 (fr)
NZ (2) NZ275472A (fr)
PL (1) PL180679B1 (fr)
PT (2) PT724583E (fr)
RU (1) RU2168511C2 (fr)
SG (2) SG59971A1 (fr)
SI (2) SI0724583T1 (fr)
SK (1) SK282491B6 (fr)
TW (1) TW406082B (fr)
UA (1) UA60291C2 (fr)
WO (1) WO1995011244A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420590D0 (en) * 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
AU2420201A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Compounds and methods for the treatment of pain
US6787547B2 (en) 1999-12-23 2004-09-07 Astrazeneca Ab Compound and method for the treatment of pain
US20030181449A1 (en) * 1999-12-23 2003-09-25 Urbanek Rebecca Ann Methods and compositions for the treatment of pain
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
EP1244663B1 (fr) * 1999-12-23 2004-08-25 AstraZeneca AB Composes et procedes pour le traitement de la douleur
JP2003518500A (ja) * 1999-12-23 2003-06-10 アストラゼネカ・アクチエボラーグ 痛みの処置のための方法および組成物
IL150202A0 (en) * 1999-12-23 2002-12-01 Astrazeneca Ab Method and composition for the treatment of pain
US6730675B2 (en) 1999-12-23 2004-05-04 Astrazeneca Ab Compounds and methods for the treatment of pain
DE60019807T2 (de) * 1999-12-23 2006-01-19 Astrazeneca Ab Pyridazino-quinolin derivat und verfahren zur behandlung von schmerz
EP1577311A1 (fr) * 1999-12-23 2005-09-21 AstraZeneca AB Sels de composé pyridazino quinoline et utilisation dans le traitement de la douleur
US6943165B2 (en) * 1999-12-23 2005-09-13 Astrazeneca Ab Compound and method for the treatment of pain
WO2001047925A1 (fr) * 1999-12-23 2001-07-05 Astrazeneca Ab Composes et methodes de traitement de la douleur
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
WO2002026738A1 (fr) * 2000-09-29 2002-04-04 Astrazeneca Ab 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES ET LEUR UTILISATION POUR TRAITER LA DOULEUR
WO2002026739A1 (fr) * 2000-09-29 2002-04-04 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones et leur utilisation pour le traitement de la douleur
US6946463B2 (en) 2000-09-29 2005-09-20 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain
JP2004509964A (ja) * 2000-09-29 2004-04-02 アストラゼネカ・アクチエボラーグ 7−クロロ−4−ヒドロキシ−2−(2−ピリジルエチル)−1,2,5,10−テトラヒドロピリダジノ[4,5−b]キノリン−1,10−ジオン及び疼痛治療のためのその使用
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
RS95003A (en) * 2001-05-31 2007-02-05 Sanofi-Aventis, Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
AU2003301513A1 (en) 2003-08-04 2005-02-15 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
ME02970B (fr) 2004-06-24 2018-07-20 Vertex Pharma Modulateurs de transporteurs de cassette de liaison a l ́ATP
US20090105272A1 (en) * 2005-12-24 2009-04-23 Grootenhuis Peter D J Prodrugs of modulators of ABC transporters
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
EP2821400B1 (fr) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Procédé pour faire des modulateurs de régulateur de conductance transmembranaire de la fibrose kystique
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
WO2013130669A1 (fr) 2012-02-27 2013-09-06 Vertex Pharmaceuticals Incorporated Composition pharmaceutique et son administration
AU2015330923B2 (en) 2014-10-07 2020-03-12 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109972D0 (en) * 1991-05-09 1991-07-03 Ici Plc Therapeutic compounds
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
GB9420590D0 (en) * 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds

Also Published As

Publication number Publication date
DE69426422T2 (de) 2001-05-10
IL111266A0 (en) 1994-12-29
FI961696A (fi) 1996-04-18
FI114916B (fi) 2005-01-31
PT724583E (pt) 2001-03-30
DE69434380T2 (de) 2006-05-04
GR3035080T3 (en) 2001-03-30
DK0724583T3 (da) 2001-03-05
DE69434380D1 (de) 2005-06-23
PT1004582E (pt) 2005-09-30
TW406082B (en) 2000-09-21
NZ275472A (en) 1998-03-25
RU2168511C2 (ru) 2001-06-10
EP1004582A2 (fr) 2000-05-31
CZ292311B6 (cs) 2003-09-17
AU721139B2 (en) 2000-06-22
PL314041A1 (en) 1996-08-05
NO961584L (no) 1996-04-19
SI0724583T1 (en) 2001-04-30
US6232313B1 (en) 2001-05-15
US6103721A (en) 2000-08-15
HK1013997A1 (en) 1999-09-17
CZ113896A3 (en) 1996-09-11
GB9420590D0 (en) 1994-11-30
JPH09504519A (ja) 1997-05-06
ATE295846T1 (de) 2005-06-15
UA60291C2 (uk) 2003-10-15
EP0724583A1 (fr) 1996-08-07
FI970907A (fi) 1997-03-03
AU688393B2 (en) 1998-03-12
PL180679B1 (en) 2001-03-30
US5744471A (en) 1998-04-28
DK1004582T3 (da) 2005-08-15
FI961696A0 (fi) 1996-04-18
CN1053189C (zh) 2000-06-07
EP1004582B1 (fr) 2005-05-18
SI1004582T1 (fr) 2005-08-31
MY132875A (en) 2007-10-31
ES2154686T3 (es) 2001-04-16
SG92630A1 (en) 2002-11-19
WO1995011244A1 (fr) 1995-04-27
HUT74161A (en) 1996-11-28
JP3583132B2 (ja) 2004-10-27
EP0724583B1 (fr) 2000-12-13
ATE198072T1 (de) 2000-12-15
NO961584D0 (no) 1996-04-19
FI970907A0 (fi) 1997-03-03
CN1138332A (zh) 1996-12-18
SG59971A1 (en) 1999-02-22
SK50496A3 (en) 1997-03-05
HU9600889D0 (en) 1996-06-28
ES2241513T3 (es) 2005-11-01
FI113865B (fi) 2004-06-30
CA2171332A1 (fr) 1995-04-27
KR100261209B1 (ko) 2000-09-01
AU7944094A (en) 1995-05-08
AU6899998A (en) 1998-07-30
NO306995B1 (no) 2000-01-24
EP1004582A3 (fr) 2000-08-30
IL111266A (en) 2002-03-10
NZ329303A (en) 2000-01-28
MY124316A (en) 2006-06-30
DE69426422D1 (de) 2001-01-18

Similar Documents

Publication Publication Date Title
SK282491B6 (sk) Pyridazíndióny, spôsob a medziprodukty na ich výrobu, farmaceutický prostriedok s ich obsahom a ich použitie
EP2922841B1 (fr) Composés pyridyle substitués par alkyl-amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifn alpha
US5475008A (en) Quinolone derivatives
US5837705A (en) Alpha-substituted pyridazino quinoline compounds
EP0115469B1 (fr) Pyrazolo(3,4-d)pyridin-3-ones condensées à un hétérocycle
JP3279633B2 (ja) ピリダジンジオン化合物
WO2018139876A1 (fr) Nouveau dérivé de [1,2,4]triazolo[4, 3-a]quinoxaline, son procédé de préparation, et composition pharmaceutique pour la prévention ou le traitement de maladies associées à la protéine bet, contenant ledit dérivé comme principe actif
EP1140855A1 (fr) Derive de tetrahydroindazole servant de ligands pour les recepteurs gaba-a alpha 5
AU705938B2 (en) Pyridazino quinoline compounds
US6214826B1 (en) Pyridazino quinoline compounds
RU2279432C2 (ru) Производные пиридазинохинолина
KR100295148B1 (ko) 피리다지노퀴놀린 화합물

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20091020